NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for future growth. Click for more on NTLA.

Oppenheimer lowered the firm’s price target on Intellia Therapeutics (NTLA) to $40 from $60 and keeps an Outperform rating on the shares after ...

Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report published ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO ...